Thuramed Tetras Asynchronous Peptide Synthesizer Exceeds Expectations
News Feb 22, 2008
In its second year of commercial sale, the Thuramed Tetras has surpassed even the parent companies, CreoSalus, expectations for sales. ‘The Tetras has been an exceptional success story for CreoSalus’ says CreoSalus representative Brian Boston.
‘Our goal was to introduce the first real change in SPPS technology in over ten years. Peptide research has advanced tremendously over the last decade, but the instrumentation had not, so we remedied that problem for researchers.’
The company says that the TETRAS allows for up to 106 50-150mg/resin reactions orup to 20 500mg-2g/resin reactions to be performed simultaneously, independently and syntheses can be added and removed by the user without disrupting other reactions.
Individualized reactors and dedicated fluid delivery stations allow for an instrument with no cross contamination and exponentially lower waste. Modular delivery stations can be removed and replaced in seconds allowing more user serviceable items than ever before and nearly no 'down time' waiting on traditional instrument service reps to arrive.
The software is fully networkable with remote operation capabilities, SynStatus™ email updates from the TETRAS to the user and online technical service and diagnostic capabilities.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.